Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Bio-Techne (TECH) to $51 from $68 and keeps an Outperform rating on ...

This was the stock's third consecutive day of losses.

Bio-Techne Corporation TECH is set to release its first-quarter fiscal 2025 results on Oct. 30, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday and set a price target of ...

StockNews.com upgraded shares of Bio-Techne (NASDAQ:TECH – Free Report) from a hold rating to a buy rating in a report released on Friday morning. Other research analysts have also recently issued ...

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to ...

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments ...